References
  1. Smolen JS, Aletaha D, McInnes IB. et al. Rheumatoid arthritis. The Lancet 2016;388 :2023-38.
  2. Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. The Lancet 2010;376 :1094-108.
  3. Favalli EG, Biggioggero M, Meroni PL. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an ‘anchor’ drug? Autoimmun Rev 2014;13 :1102-8.
  4. Cantini F, Nannini C, Niccoli L et al. Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice. Autoimmun Rev 2015;14 :503-9.
  5. Nimmerjahn F,  Ravetch JV. Fcgamma receptors as regulators of immune responses Nat Rev Immunol . 2008;8 :34-47.
  6. Kaneko Y, Nimmerjahn F, Ravetch JV et al. Among authors: ravetch jv. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006;313 :670-3.
  7. Hodge JA, Kawabata TT, Krishnaswami S et al. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol. 2016;34 :318-28.
  8. Epstein O. The spatial homeostasis hypothesis // Symmetry. – 2018;10: 103.
  9. Dugina JL, Petrov VI, Babayeva AR et al. A randomized, open-label, comparative, 6-month trial of oral ultra-low doses of antibodies to tumor necrosis factor-α and diclofenac in rheumatoid arthritis // International Journal of Tissue Reactions 2005;XXVII (1): 15-21.
  10. Ivana Jovčevska , Serge Muyldermans. The Therapeutic Potential of Nanobodies. BioDrugs 2020;34 :11-26.
  11. Imbach P, Barandun S,  d’Apuzzo V et al.  High-dose intravenous γ‑globulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1 (8232):1228-31
  12. https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/immune-globulin-intravenous-igiv-indications
  13. Zandman-Goddard G, Krauthammer A, Levy Y, et al. Long-term therapy with intravenous immunoglobulin is beneficial in patients with autoimmune diseases. Clin Rev Allergy Immunol 2012;42 :247–55.
  14. Katz U, Shoenfeld Y, Zandman-Goddard G. Update on intravenous immunoglobulins (IVIg) mechanisms of action and off-label use in autoimmune diseases. Curr Pharm Des 2011;17 :3166-75.
  15. Ephrem A, Misra N, Hassan G et al. Immunomodulation of autoimmune and inflammatory diseases with intravenousimmunoglobulin. Clin Exp Med 2005 5 :135-40.
  16. Bayry J, Negi VS, Kaveri SV et al. Intravenous immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol 2011;7 :349-59.
  17. Katz-Agranov N, Khattri S, Zandman-Goddard G. The role of intravenous immunoglobulins in the treatment of rheumatoid arthritis. Autoimmun Rev 2015 14 :651–8.
  18. Mulhearn B, Bruce IN.Mulhearn B, et al. Indications for IVIG in rheumatic diseases. Rheumatology (Oxford) 2015;54 :383-91.
  19. Levy Y, Sherer Y, Langevitz Pet al. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin - a preliminary report. Clin Rheumatol 2000;19 : 207-11.
  20. Amital H, Levy Y, Shoenfeld Y. Use of intravenous immunoglobulin in livedo vasculitis. Clin Exp Rheumatol 2000;18 : 404-6.
  21. Meissner M, Sherere Y, Levy Y. Chwalinska H, Langevitz P, Shoenfeld Y. Intravenous immunoglobulin therapy in a patient with lupus serositis and nephritis. Rheumatol Int 2000;19 :199-201.
  22. Levy Y, Amital H, Langevitz P et al. Intravenous immunoglobulin modulates cutaneous involvement and reduces skin fibrosis in systemic sclerosis: an open-label study. Arthritis Rheumatology 2004;50 :1005-7.
  23. Shoenfeld Y, Krause I. IVIG for autoimmune, fibrosis, and malignant conditions: our experience with 200 patients. J Clin Immunol 2004;24 :107-14.
  24. Levy Y, Sherer Y, Ahmed A et al. Autoantibody level modification in adult patients with idiopathic thrombocytopenic purpura following intravenous immunoglobulin treatment. Nat Immun 1998;16 : 207-24.
  25. Muscat C, Bertotto A, Ercolani R et al. Long term treatment of rheumatoid arthritis with high doses of intravenous immunoglobulins: effects on disease activity and serum cytokines. Ann Rheum Dis 1995;54 :382–5.
  26. Tumiati B, Casoli P, Veneziani M, Rinaldi G. High-dose immunoglobulin therapy as an immunomodulatory treatment of rheumatoid arthritis. Arthritis Rheumatol 1992; 35 :1126–33.
  27. Kazatchkine MD, and SV Kaveri. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345 :747–55.
  28. Kaneko Y, Nimmerjahn F, Ravetch JV et al. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science. 2006;313 :670-3.
  29. Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J.Modulation of the cellular immune system by intravenous immunoglobulin. Trends Immunol 2008; 29 :608–15.
  30. Schwab I, and F Nimmerjahn. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013;13 :176–89.
  31. Washburn N, Schwab I, Ortiz D et al. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc Natl Acad Sci U S A. 2015;112 :E1297-306.
  32. Miyoshi M, Liu S.Miyoshi M, et al. Collagen-Induced Arthritis Models. Methods Mol Biol. 2018;1868 :3-7
  33. Bashi T, Shovman O, Fridkin M et al. Novel therapeutic compound tuftsin-phosphorylcholine attenuates collagen-induced arthritis. Clin Exp Immunol 2016;184 :19-28.
  34. Blank M, Bashi T, Lachnish J et al. Helminths-based bi-functional molecule, tuftsin-phosphorylcholine (TPC), ameliorates an established murine arthritis. PLoS One. 2018;13 :e0200615.
  35. Svetlicky N, Kivity S, Odeh Q et al. immunoglobulin attenuates collagen-induced arthritis in mice. Clin Exp Immunol. 2015;182 :241-50.
  36. Park E, Cho M, Ki CS. Correct use of repeated measures analysis of variance. Korean J Lab Med 2009;29 :1-9..
  37. Gertel S, Serre G, Shoenfeld Y, Amital H. Immune tolerance induction with multiepitope peptide derive from citrullinated autoantigens attenuates arthritis manifestations in adjuvant arthritis rats. J Immunol. 2015; 194: 5674-80.
  38. Lee SY, Jung YO, Ryu JG et al. Intravenous immunoglobulin attenuates experimental autoimmune arthritis by inducing reciprocal regulation of Th17 and Treg cells in an interleukin-10-dependent manner. Arthritis Rheumatol 2014; 66 :1768-7.
  39. Christensen AD, Haase C, Cook AD, Hamilton JA. K/BxN serum-transfer arthritis as a model for human inflammatory arthritis. Front Immunol 2016;7 :213-7.
  40. Lewis BJB, Ville J, Blacquiere M, et al. Using the K/BxN mouse model of endogenous, chronic, rheumatoid arthritis for the evaluation of potential immunoglobulin-based therapeutic agents, including IVIg and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer. BMC Immunol 2019;20:44-54.
  41. Le Pottier L, Sapir T, Bendaoud B, Youinou P, Shoenfeld Y, Pers JO. Itravenous immunoglobulin and cytokines. Focus on tumor necrosis factor family members BAFF and APRIL. Ann NY Acad Sci 2007;1110 : 426-32.
  42. Sherer Y, Wu R, Krause I et al. Cytokine levels in various intravenous immunoglobulin (IVIg) preparations. Hum Antibodies 2001;10:51-3.
  43. Bendtzen K, Hansen MB, Ross C et al. Stem Cells. Cytokines and autoantibodies to cytokines 1995;13 :206-22.
  44. Cervera R, Rodríguez-Pintó I, Espinosa G.Cervera R, et al. The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. J Autoimmun 2018;92 :1-11.
  45. Liu Q, Zhou YH, Yang ZQ et al. The cytokine storm of severe influenza and development of immunomodulatory therapy. Cell Mol Immunol 2016;13 :3-10.
  46. Davey RT Jr, Fernבndez-Cruz E, Markowitz N et al. Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG):a double-blind, randomised, placebo-controlled trial. Lancet Respir Med 2019;7 : 951–63.
  47. Mehta P, McAuley DF, Brown M et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020;395 :1033-4.
  48. Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S. Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 2020;39 :2085-94.
  49. Domínguez-Soto Á, Simón-Fuentes M, de Las Casas-Engel M et al. IVIg Promote Cross-Tolerance against Inflammatory Stimuli In Vitro and In Vivo. J Immunol 2018;201 :41-52.
  50. Ohmi Y, Ise W, Harazono A, Takakura D et al. Sialylation converts arthritogenic IgG into inhibitors of collagen-induced arthritis. Nat Commun 2016;7 :11025-37.
  51. Campbell IK, Miescher S, Branch DR et al. Therapeutic effect of IVIG on inflammatory arthritis in mice is dependent on the Fc portion and independent of sialylation or basophils. J Immunol 2014;192 :5031-8.